Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (364)	11/21/1999 8:29:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 1169

you left off the punch line...... Guess you'll need to re-read The Billion Dollar Molecule for the much longer and gossipier version of Casaubon's post. Made it more frustrating that some of these proteins (cyclophilin at least; I am too lazy to check on FKBP12 et al.) have proline isomerase activity, which led people to believe initially that these were classic enzyme drug targets. Calcineurin and the rest of the story explained why nothing simple worked. Thanks to Casaubon from this end too. PB